Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.

Breast cancer research and treatment - 1 Jun 2018

Costa Ricardo L B, Han Hyo Sook, Gradishar William J

Abstract excerpt

PURPOSE: Triple-negative breast cancer (TNBC) accounts for approximately 20% of breast cancer cases. Although there have been advances in the treatment of hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancers, targeted therapies for TNBC remain unavailable. In this narrative review, we summarize recent discoveries related to the underlying biology of the phosphoinositide...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Gene Expression Regulation, Neoplastic
Share to Molecular Targeted Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phosphatidylinositol 3-Kinase

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-akt

Share to TOR Serine-Threonine Kinases

Share to Triple Negative Breast Neoplasms

Source

Identifiers

PMID: 29417298
DOI: 10.1007/s10549-018-4697-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.PMID 29417298Read ↗

Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical ChallengesSemantic proximity Read ↗

Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.Semantic proximity Read ↗

Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTORSemantic proximity Read ↗

Mutational Landscape of PI3K-AKT-mTOR Pathway in Breast Cancer: Implications for Targeted TherapeuticsSemantic proximity Read ↗

The Biological Roles and Clinical Applications of the PI3K/AKT Pathway in Targeted Therapy Resistance in HER2-Positive Breast Cancer: A Comprehensive ReviewSemantic proximity Read ↗

Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients.Semantic proximity Read ↗

Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer.Semantic proximity Read ↗

Molecular targets and therapies associated with poor prognosis of triple‑negative breast cancer (Review)Semantic proximity Read ↗

Role of PTEN, PI3K, and mTOR in Triple-Negative Breast CancerSemantic proximity Read ↗

PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trialsSemantic proximity Read ↗

Molecular Pathways: PI3K Pathway Targets in Triple-Negative Breast CancersSemantic proximity Read ↗

Spectrum of PIK3CA/AKT mutations across molecular subtypes of triple-negative breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.